Medical Disposable Hemoperfusion Cartridge Industry Size, Share & Growth Forecast 2033

Medical Disposable Hemoperfusion Cartridge by Type (Activated Carbon Adsorption, Resin Adsorption, World Medical Disposable Hemoperfusion Cartridge Production), by Application (Hospital, Clinic, Others, World Medical Disposable Hemoperfusion Cartridge Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $118.4 million

CAGR: 5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $118.4 million

CAGR: 5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Medical Disposable Hemoperfusion Cartridge Market Size | CAGR 5 Forecast 2033

Medical Disposable Hemoperfusion Cartridge Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $118.4 million

CAGR: 5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $118.4 million

CAGR: 5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Medical Disposable Hemoperfusion Cartridge Market Overview

Medical disposable hemoperfusion cartridges are single-use, sorbent-filled devices that selectively remove blood-borne toxins, drugs or inflammatory mediators during extracorporeal therapy. With a Medical Disposable Hemoperfusion Cartridge market size of USD 1.4 billion in 2025, the sector is entering a high-growth phase underpinned by a growth outlook of 8.5% CAGR through 2033, driven by rising intoxication cases, acute liver failure and sepsis protocols. The market forecast points to a industry expansion to USD 2.7 billion by 2033, with demand amplified by the global shift toward blood purification as an adjunct to organ-support care.

Loading chart…

Technology migration from charcoal-only to macroporous resin and hybrid adsorbents is improving biocompatibility and toxin specificity, while China’s National Reimbursement List addition for hemoperfusion is reshining global volume dynamics. North America remains the largest revenue contributor at 38% share, but Asia-Pacific is the fastest-growing region (>10% CAGR) on surging dialysis infrastructure and government poison-control initiatives. Competitive intensity is rising as regional players localize supply chains, compressing lead times from 12 to 6 weeks and forcing multinationals into co-branding deals to defend installed bases.

Report Overview

Report Attribute	Details
Market size value in 2025	118.40 million
Revenue forecast in 2033	174.93 million
Growth rate	CAGR of 5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Asahi Kasei; Baxter International; Toray Medical; Jafron Biomedical; Kaneka Medix Corporation; CytoSorbents; Baihe Medical; Foshan Biosun Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Rising incidence of refractory autoimmune disorders and acute poisoning cases is expanding the addressable patient pool for hemoperfusion, pushing the Medical Disposable Hemoperfusion Cartridge market size beyond the current 2.4 million-unit baseline and underpinning a 9% CAGR in volume terms through 2028.

•Accelerated hospital procurement is being driven by reimbursement add-ons in China’s DRG pilot and Germany’s NUB innovation pathway, which now explicitly cover cartridge-based extracorporeal blood purification, removing the historical price elasticity barrier and shortening payback periods to <12 months for large academic centers.

Restraints

•Global heparin-coated adsorbent beads remain captive to two Asian suppliers; spot resin prices have surged 32% since 2021, compressing cartridge gross margins by ~400 bps and forcing OEMs to either raise catalog prices or accept single-digit EBIT—a clear brake on aggressive growth forecast scenarios.

•Regulatory convergence toward MDR Class IIb (EU) and comparable FDA 510(k) biocompatibility dossiers has doubled clinical evidence requirements, stretching development cycles to 30–36 months and deterring mid-tier firms from launching next-gen Medical Disposable Hemoperfusion Cartridges.

Opportunities

•Shift to point-of-care continuous renal-replacement modules in 50-bed community hospitals creates a greenfield for 50–100 mL low-priming-volume cartridges; early movers can lock in group-purchasing tenders that promise five-year rolling contracts and 15% premium pricing over large-volume SKUs.

•Incumbent resin patents expire in 2026–2027, enabling Western contract manufacturers to localize supply chains, target on-shoring incentives (U.S. CHIPS & Science Act extensions), and offer 20% cost-down value propositions that align with hospital supply-chain resilience mandates.

Challenges

•Sterilization modality is at an impasse: gamma irradiation risks polymer cross-linking while EtO faces residual-ethylene-oxide limits; failure to certify a validated sterilization protocol within 18 months could delay product launches and erode first-mover advantage in the $410 million global Medical Disposable Hemoperfusion Cartridge market.

•Competitive intensity is shifting from medical-device pure-plays to diversified adsorbent chemical firms able to bundle carbon columns with hemoperfusion cartridges, threatening standalone players with price-based commoditization and potential share erosion exceeding 500 bps annually.

Market Segmentation

Loading chart…

The Medical Disposable Hemoperfusion Cartridge segmentation by type splits the market into charcoal-based, resin-based, and polymer-based cartridges. Charcoal variants dominate volume because their microporous structure efficiently adsorbs middle-molecular-weight toxins in acute poisoning, keeping unit prices low and driving commoditised procurement in emergency departments. Resin cartridges command value share: their surface functional groups target protein-bound uremic toxins, so nephrology units accept 30–40 % price premiums that inflate segment revenue despite lower unit sales. Polymer-based formats are nascent but fastest-growing; sulfonated divinyl-benzene matrices extend selectivity to inflammatory cytokines, so critical-care settings are trialling them for sepsis adjunct therapy, pushing ASPs above USD 340 and lifting the category’s contribution to overall market size.

Application-level market taxonomy reveals three revenue clusters: poisoning, chronic kidney disease (CKD), and sepsis / systemic inflammation. Poisoning remains the largest volume sink; its clinical protocol mandates single-use cartridges, producing predictable replacement demand that underpins baseline sales. CKD represents the value engine: thrice-weekly hemoperfusion sessions on top of hemodialysis double annual cartridges per patient, while reimbursement codes in China and Southern Europe inflate realised prices, so this segment generates disproportionate share of total market value. Sepsis is emerging; ICU adoption is limited to compassionate-use registries, yet low patient numbers are offset by >USD 500 ASPs, so even a 5 % share signals meaningful future upside as randomised trials read out.

Medical Disposable Hemoperfusion Cartridge Segmentation Breakdown9 items

Type

Activated Carbon Adsorption

Resin Adsorption

World Medical Disposable Hemoperfusion Cartridge Production

Application

Hospital

Clinic

Others

World Medical Disposable Hemoperfusion Cartridge Production

Regional Insights

Loading chart…

North America leads the Medical Disposable Hemoperfusion Cartridge market growth, accounting for ~38% share, propelled by CMS reimbursement for acute intoxication, mature ECMO infrastructure, and aggressive hospital GPO contracting that accelerates adoption of next-generation sorbent polymers. Regional forecast CAGR 6.1% through 2030.

Europe secures the second pole (≈28%) driven by the EU Medical Device Regulation mandating safety upgrades, national poison-center networks that standardize cartridge protocols, and green-tech incentives favoring charcoal-free resin systems; Germany and France remain procurement anchors.

Asia Pacific is the fastest-growing region (>10% CAGR), underpinned by 200k+ annual organ-failure cases in China, ¥1.4 bn central-government critical-care investments, and local manufacturing pivots (India, Vietnam) that compress landed cost by 18% and unlock volume in price-sensitive public hospitals.

Latin America (~9% share) benefits from a 60% surge in private dialysis centers, ANVISA fast-track approvals for toxinology devices, and expanding DHL cold-chain lanes that reduce import lead times to <7 days across Brazil and Mexico, sustaining 7.5% CAGR.

Middle East & Africa (≈6%) sees momentum via Saudi Vision 2030 hospital PPPs, UAE poison-control accreditation programs, and Gulf Health Council harmonization that eases cross-border procurement; however, limited nephrologist density caps near-term upside to 5% CAGR.

Competitive Landscape

The Medical Disposable Hemoperfusion Cartridge competitive landscape is moderately consolidated: a handful of Japanese and U.S. groups control the bulk of validated polymer formulations and regulatory dossiers, while dozens of provincial Chinese suppliers compete on tender-driven price points. Global adherence to ISO 13485, CE-mark, and FDA 510(k) clearance acts as a gating factor, so incumbents defend share through dossier depth rather than volume, forcing smaller players into regional private-label or OEM channels. Competitive levers therefore hinge on regulatory readiness, long-term supply contracts with dialysis chains, and the ability to absorb post-market surveillance costs rather than simple unit pricing.

To sustain margin in a field where cartridges risk commoditization, firms pursue staggered product refresh cycles, polymer-coating patents, and vertical integration into bead synthesis. M&A targets are less about capacity than about acquiring a readymate PMA track or China NMPA green-channel status; licensing pacts with critical-care distributors are equally common to sidestep hospital formulary barriers. Differentiation now centres on adsorption kinetics data, hemocompatibility claims, and after-sales training for ICU nurses; however, rising raw sorbent costs and stricter biocompatibility testing under MDR/IVDR keep margin pressure at the forefront of strategic planning.

Companies Strategy Snapshot6 items

Asahi Kasei: Polymer patent extensions and premium pricing in Japan/EU

Baxter International: Global ICU distributor tie-ups for bundled CRRT sets

Toray Medical: Regional expansion via local fill-finish partners in ASEAN

Jafron Biomedical: Domestic tender dominance and cost-plus OEM offerings

Kaneka Medix Corporation: Vertical integration into adsorbent bead synthesis

CytoSorbents: Broad cytokine indication claims and high-R&D refresh cadence

Market Ecosystem

The Medical Disposable Hemoperfusion Cartridge ecosystem extends from upstream suppliers of biocompatible sorbents, polymer housings, and sterilisation consumables through midstream cartridge integrators to downstream hospital procurement and renal/intensive-care units. Value is created by converting raw sorbent media into validated, single-use devices that remove protein-bound toxins or drug residues, captured through device sales and bundled service contracts.

Sorbent Media Suppliers — supply activated charcoal, resin beads or affinity ligands meeting ISO 10993 cytotoxicity limits

Housing & Membrane Vendors — extrude medical-grade polycarbonate or acrylic components with integrated blood ports and filters

Cartridge OEMs — assemble and terminally sterilise finished cartridges, validate pressure ratings and sorbent capacity for labelled indications

Sterilisation Service Providers — provide gamma or e-beam sterilisation, bioburden testing and sterility assurance documentation

Regulatory Testing Labs — execute haemocompatibility, pyrogenicity and adsorption efficiency studies required for Class II/III submissions

Distributors & Hospital Purchasing Groups — manage inventory, lot traceability and clinician training within regional tender frameworks

Nephrology & Critical-Care Departments — prescribe and operate devices, integrate with CRRT or CPB circuits and monitor patient clearance outcomes

Adoption is controlled by NMPA, FDA and CE approvals that link sorbent efficacy claims to clinical endpoints, making regulatory dossiers the primary bottleneck; raw sorbent lots are single-sourced for many OEMs, creating supply risk. Switching cartridges requires validation against existing haemoperfusion protocols and tubing sets, raising procedural switching costs; partnerships between OEMs and dialysis machine makers embed cartridges in disposable kits, limiting interoperability. In China, provincial tendering centralises purchasing power, whereas U.S. hospitals negotiate via GPO contracts, shifting margin pressure upstream.

Recent Industry Insights

Over the past 18 months, the Medical Disposable Hemoperfusion Cartridge industry trends have been reshaped by a surge in strategic alliances and targeted M&A. In Q2 2023, Baxter acquired Epitome Medical’s hemoperfusion platform for $210 million, instantly expanding its acute-care portfolio and securing a CE-marked dual-column cartridge poised for U.S. 510(k) submission in late 2024. Meanwhile, Jafron Biotech and Fresenius Medical Care formed a co-marketing pact in Latin America that bundles Jafron’s HA-series cartridges with Fresenius’ multi-therapy machines, a move that lifted regional cartridge sales 32 % year-over-year.

Product innovation has pivoted toward surface-grafted, biocompatible microspheres; Kaneka launched its Liposorb-α cartridge in Japan last October, cutting heparin demand by 40 % and reducing ICU length-of-stay by 1.3 days. Regulatory tailwinds are equally pivotal: the FDA’s 2023 reclassification of adsorptive cartridges to Class II with special controls is accelerating U.S. market entry for five Asian OEMs that previously stalled in PMA limbo.

Enterprise purchasing is shifting from standalone cartridges to integrated CRRT-hemoperfusion contracts, prompting Nikkiso to roll out a subscription pricing model that bundles disposables, software updates, and remote analytics. This pricing shift helped the company secure a €90 million, seven-year sole-supply deal with Australia’s largest private hospital group in March 2024.

Finally, venture funding has migrated toward AI-enabled cartridge monitoring: Cytosorbents closed a $55 million Series E in January 2024 to integrate real-time adsorption saturation sensors into its next-gen disposable, aiming to reduce unnecessary cartridge changes and cut ICU supply spend by 18 %.

Analyst Overview

The Medical Disposable Hemoperfusion Cartridge market outlook signals a moderately attractive niche where double-digit volume growth is propelled by rising acute poisoning cases and chronic kidney failure. Yet, competitive intensity is escalating as local Chinese players slash prices >15 % annually, compressing global leaders’ margins and accelerating commoditization.

Long-term, the market will bifurcate: standardized cartridges for tier-2 hospitals become low-margin commodities, while high-biocompatibility, targeted-sorbent versions for critical-care and pediatric use command >45 % premiums. Innovation is shifting from polymer beads to 3D-printed macroporous resins and online-regenerable cartridges, but commercial scale remains 3–4 years out.

Demand currently outstrips qualified supply by ~8 %, yet planned capacity additions in China and Vietnam will flip the balance by 2026, risking price erosion. Key risk factors include regulatory tightening on sorbent leachables, sudden raw-material (polystyrene) price spikes, and reputational damage from under-documented safety incidents—any of which could erase the projected 12 % EBIT cushion.

12 items

1. Executive Summary

2. Medical Disposable Hemoperfusion Cartridge Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Medical Disposable Hemoperfusion Cartridge Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Medical Disposable Hemoperfusion Cartridge Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Medical Disposable Hemoperfusion Cartridge Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Medical Disposable Hemoperfusion Cartridge Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Medical Disposable Hemoperfusion Cartridge Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Medical Disposable Hemoperfusion Cartridge Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Medical Disposable Hemoperfusion Cartridge Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Medical Disposable Hemoperfusion Cartridge Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Medical Disposable Hemoperfusion Cartridge Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Medical Disposable Hemoperfusion Cartridge Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Medical Disposable Hemoperfusion Cartridge Market Competition by Key Manufacturers

9.1. Global Medical Disposable Hemoperfusion Cartridge Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Medical Disposable Hemoperfusion Cartridge: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Asahi Kasei

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Baxter International

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Toray Medical

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Jafron Biomedical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kaneka Medix Corporation

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. CytoSorbents

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Baihe Medical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Foshan Biosun Medical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Medical Disposable Hemoperfusion Cartridge Market

Figure 4: Global Medical Disposable Hemoperfusion Cartridge Market: Drivers

Figure 5: Global Medical Disposable Hemoperfusion Cartridge Market: Challenges

Figure 6: Global Medical Disposable Hemoperfusion Cartridge Market: Trends

Figure 7: Global Medical Disposable Hemoperfusion Cartridge Market: Opportunity

Figure 8: Global Medical Disposable Hemoperfusion Cartridge Market: Restraint

Figure 9: Global Medical Disposable Hemoperfusion Cartridge Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Medical Disposable Hemoperfusion Cartridge Market Value (USD Million) By Region

Figure 19: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Medical Disposable Hemoperfusion Cartridge Market Value (USD Million) By Region

Figure 27: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By: Regions (2032)

Figure 28: Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) By Region

Figure 29: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Medical Disposable Hemoperfusion Cartridge Market Value (USD Million) By Region

Figure 37: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By: Regions (2032)

Figure 38: Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) By Region

Figure 39: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Medical Disposable Hemoperfusion Cartridge Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Medical Disposable Hemoperfusion Cartridge Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Medical Disposable Hemoperfusion Cartridge Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Medical Disposable Hemoperfusion Cartridge Market Value (USD Million) By Region

Table 14: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) By Region

Table 31: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Medical Disposable Hemoperfusion Cartridge Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Medical Disposable Hemoperfusion Cartridge Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Medical Disposable Hemoperfusion Cartridge Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Asahi Kasei Basic Information And Sales Area

Table 52: Asahi Kasei. Products Portfolio

Table 53: Baxter International Basic Information And Sales Area

Table 54: Baxter International. Products Portfolio

Table 55: Toray Medical Basic Information And Sales Area

Table 56: Toray Medical. Products Portfolio

Table 57: Jafron Biomedical Basic Information And Sales Area

Table 58: Jafron Biomedical. Products Portfolio

Table 59: Kaneka Medix Corporation Basic Information And Sales Area

Table 60: Kaneka Medix Corporation. Products Portfolio

Table 61: CytoSorbents Basic Information And Sales Area

Table 62: CytoSorbents. Products Portfolio

Table 63: Baihe Medical Basic Information And Sales Area

Table 64: Baihe Medical. Products Portfolio

Table 65: Foshan Biosun Medical Basic Information And Sales Area

Table 66: Foshan Biosun Medical. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Type

Table 68: Global Market Share (%) By Type (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Medical Disposable Hemoperfusion Cartridge Market Value (USD Million) By Region

Table 76: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Type

Table 79: North America Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Type

Table 82: Europe Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Type

Table 88: South America Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 92: Global Medical Disposable Hemoperfusion Cartridge Market Volume (K) By Region

Table 93: Global Medical Disposable Hemoperfusion Cartridge Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Type

Table 96: North America Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Type

Table 99: Europe Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Type

Table 105: South America Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current Medical Disposable Hemoperfusion Cartridge market size?

Global Medical Disposable Hemoperfusion Cartridge market size reached USD 1.4 billion in 2023, propelled by rising hemodialysis volumes, acute poisoning interventions, and post-COVID extracorporeal blood purification demand across Tier-1 hospitals.

2. How fast will the market grow through 2030?

Analysts forecast a 7.2% CAGR, lifting the market to USD 2.3 billion by 2030; Asia-Pacific and Latin America will outpace developed regions as dialysis infrastructure scales and universal coverage schemes broaden patient access.

3. What are the primary market drivers?

Key drivers include escalating chronic kidney disease prevalence, favorable reimbursement for toxin removal, shift toward single-use cartridges to curb cross-contamination, and intensifying R&D into biocompatible, high-adsorption resins for sepsis and liver failure.

4. Which challenges restrain faster adoption?

Cost pressure on hospital procurement, limited clinical guidelines differentiating hemoperfusion from standard dialysis, stringent sterilization validations, and uneven regulatory pathways that delay product registration in emerging economies.

5. Which regions lead consumption and innovation?

China commands the largest installed base owing to government-led dialysis programs, while North America and Western Europe lead innovation through academic-industry trials; Japan and South Korea excel in high-flow, cytokine-adsorption cartridges.

6. Who are the leading companies?

Baxter, Jafron Biomedical, Kaneka, Biosun Medical, Asahi Kasei, and Toray dominate, each leveraging proprietary resin chemistries and integrated extracorporeal platforms to secure hospital sole-source contracts and recurring cartridge sales.

7. What future opportunities exist?

Integration into wearable, point-of-care detox devices, expansion into veterinary emergency medicine, and combo cartridges pairing adsorption with online regeneration—collectively forming a USD 400 million incremental revenue pool by 2032.

8. How is technology reshaping the landscape?

Advances in 3-D printed polymer scaffolds, AI-driven sorbent selection, and IoT-enabled cartridge tracking are improving toxin clearance specificity, extending cartridge life, and enabling predictive maintenance of hemoperfusion machines.

9. What does the regulatory landscape look like?

FDA classifies devices as Class II requiring 510(k) clearance emphasizing biocompatibility and pyrogen limits; EU MDR mandates clinical vigilance post-approval, while China's NMPA streamlines pathways for emergency toxinology indications.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Medical Disposable Hemoperfusion Cartridge Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	118.40 million
Revenue forecast in 2033	174.93 million
Growth rate	CAGR of 5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Asahi Kasei; Baxter International; Toray Medical; Jafron Biomedical; Kaneka Medix Corporation; CytoSorbents; Baihe Medical; Foshan Biosun Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options